A Phase II Study to Evaluate Safety and Efficacy of Combined Treatment With Ipilimumab and Intratumoral Interleukin-2

NCT01480323 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

15

Enrollment

OTHER

Sponsor class

Conditions

Malignant Melanoma

Interventions

DRUG: Interleukin-2
DRUG: Ipilimumab

Sponsor

University Hospital Tuebingen